-
Study aim
-
In-vivo Bioequivalence Study of Metformin 500 mg FC. Tablets of The Test Drug ( Sajjad Darou, Iran) in Compared with The Reference Drug (GLUCOPHAGE® 500 mg. Merck Serono, Germany) In Iranian Healthy Volunteers
-
Design
-
Bioequivalence study, crossover, single-blinded, 24 healthy volunteers. Simple randomization was used for randomization
-
Settings and conduct
-
The study is a single-blinded (Volunteers), cross-over and feding, and on two series of healthy volunteers. The study will be done in two periods (24h). The interval between these two periods is a week. In the first round of the study, the candidates were divided into two groups the first group received a test tablet and the second group received a brand tablet. Blood samples are collected immediately before and after drug administration by volunteers. Then, drug extraction is done and samples are ready for analysis. Sampling is performed in Radin laboratory in Tabriz.
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria: General Health (Liver, Heart, and Kidney), Body Mass Index (18-28), Informed consent, Age (18-55 years old) Exclusion criteria: Smoking, History of cardiovascular disease, History of liver and kidney disease, Alcohol and drug addiction, History of allergy to metformin
-
Intervention groups
-
Intervention group 1:(GLUCOPHAGE® 500 mg. Merck Serono, Germany) as a reference Intervention group 2: Metformin 500 mg FC. Tablets manufactured by Sajjad Darou, as a test
-
Main outcome variables
-
Maximum drug concentration, Time to reach maximum drug concentration